Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)’. The study aims to determine if the combination of odronextamab and lenalidomide is more effective and safer than the current standard treatment of rituximab and lenalidomide for patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL).
The trial is testing odronextamab, an experimental bispecific antibody, combined with lenalidomide. This combination is intended to improve treatment outcomes for patients with FL and MZL, which are subtypes of Non-Hodgkin’s lymphoma.
The study is interventional with a randomized, parallel assignment model and no masking. Its primary purpose is treatment. The trial is divided into two parts: Part 1 focuses on safety and dosage, while Part 2 compares the efficacy of the new combination against the standard treatment.
The study began on December 28, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on August 20, 2025. These dates are crucial as they indicate the study’s progress and potential timelines for results.
This clinical update could influence Regeneron’s stock performance positively if the results show significant efficacy and safety improvements. Investors should monitor this study closely, as successful outcomes could enhance Regeneron’s competitive position in the oncology market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.